Surrogate end points: studying their benefits, taxonomy, and semantics. by Aronson, J

Live long and prosper: a mass strategy for treating the factors associated with ischaemic heart disease and stroke. by Aronson, J

Open access publishing: too much oxygen? by Aronson, J

One hundred years of atrial fibrillation. by Aronson, J

Observational evidence for determining drug safety: Too high a pedestal. by Aronson, J

Signs of love, not a love potion. by Aronson, J

The role of the Na+, K+-ATPase in the regulation of vascular smooth-muscle contractility, and its relationship to essential hypertension. by Aronson, J

When I use a word ... Ordinary words with extraordinary meanings. by Aronson, J

What is a clinical trial? by Aronson, J

"Open-access" publishing: first the evidence--then the verdict. by Aronson, J

AROMATIC PEES by Aronson, J

In defence of polypharmacy. by Aronson, J

Medicine in Staffordshire. by Aronson, J

The imp in the bottle. by Aronson, J

Something new every day: defining innovation and innovativeness in drug therapy. by Aronson, J

Write on. by Aronson, J

Citation classics in the British Journal of Clinical Pharmacology, 1974-2003. by Aronson, J

Surrogate end points: Studying their benefits, taxonomy, and semantics by Aronson, J

Medication reconciliation by Aronson, J

Features of this month's Journal by Aronson, J